-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Royal Bank of Canada Increases Abcam (NASDAQ:ABCM) Price Target to GBX 2,200
Royal Bank of Canada Increases Abcam (NASDAQ:ABCM) Price Target to GBX 2,200
Abcam (NASDAQ:ABCM – Get Rating) had its price target hoisted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research note published on Wednesday, The Fly reports.
Separately, Panmure Gordon upgraded Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
Get Abcam alerts:Abcam Stock Performance
ABCM opened at $16.68 on Wednesday. The business has a fifty day moving average of $14.91 and a 200 day moving average of $15.54. Abcam has a 52-week low of $12.54 and a 52-week high of $24.00.
Institutional Investors Weigh In On Abcam
Several hedge funds have recently made changes to their positions in ABCM. 2Xideas AG purchased a new stake in shares of Abcam in the 4th quarter worth $16,691,000. Brown Advisory Inc. lifted its holdings in shares of Abcam by 23.7% in the 1st quarter. Brown Advisory Inc. now owns 2,914,399 shares of the company's stock worth $53,373,000 after buying an additional 558,299 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Abcam by 26.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,553,124 shares of the company's stock worth $22,458,000 after buying an additional 323,670 shares during the period. BlackRock Inc. lifted its holdings in shares of Abcam by 26.9% in the 1st quarter. BlackRock Inc. now owns 1,473,409 shares of the company's stock worth $26,948,000 after buying an additional 311,896 shares during the period. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Abcam in the 1st quarter worth $5,028,000. 11.82% of the stock is currently owned by hedge funds and other institutional investors.Abcam Company Profile
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Featured Stories
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
Abcam (NASDAQ:ABCM – Get Rating) had its price target hoisted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research note published on Wednesday, The Fly reports.
据The Fly报道，在周三发布的一份研究报告中，加拿大皇家银行将Abcam(纳斯达克：ABCM-GET评级)的目标价从1,700英镑(20.54美元)上调至2,200英镑(26.58美元)。
Separately, Panmure Gordon upgraded Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
另外，Panmure Gordon在9月5日星期一的一份报告中将Abcam的评级从持有上调至买入。
Abcam Stock Performance
Abcam股票表现
ABCM opened at $16.68 on Wednesday. The business has a fifty day moving average of $14.91 and a 200 day moving average of $15.54. Abcam has a 52-week low of $12.54 and a 52-week high of $24.00.
ABCM周三开盘报16.68美元。该业务的50日移动均线切入位为14.91美元，200日移动均线切入位为15.54美元。Abcam的52周低点为12.54美元，52周高位为24.00美元。
Institutional Investors Weigh In On Abcam
机构投资者在Abcam上发表看法
Abcam Company Profile
Abcam公司简介
(Get Rating)
(获取评级)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Abcam plc是一家生命科学公司，专注于识别、开发和分发用于科学研究、诊断和药物发现的试剂和工具。它的主要产品包括一抗和二抗；结合抗体和结合试剂盒；单链和多重免疫分析；包括细胞因子的蛋白质和多肽；编辑的细胞系和裂解产物；以及各种其他产品，包括细胞活动试剂盒、miRNA试剂盒、生物化学品和细胞信号途径工具。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免费获取关于abcam(ABCM)的StockNews.com研究报告
- 第四季度值得考虑的3家银行
- 股市：红海中的三座强国
- 有什么办法可以治愈Teladoc股票的问题吗？
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
接收abcam日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Abcam和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧